These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19242289)

  • 21. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomoxetine for attention deficit/hyperactivity disorder.
    Garces K
    Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic treatment of attention-deficit hyperactivity disorder.
    Greydanus DE
    Indian J Pediatr; 2005 Nov; 72(11):953-60. PubMed ID: 16391451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-stimulant treatment of attention-deficit/hyperactivity disorder.
    Pliszka SR
    CNS Spectr; 2003 Apr; 8(4):253-8. PubMed ID: 12679740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment and treatment of attention-deficit/hyperactivity disorder: part 2.
    French WP
    Pediatr Ann; 2015 Apr; 44(4):160-8. PubMed ID: 25875981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [My child is so restless].
    Schlamp D
    MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder.
    Handen BL; Taylor J; Tumuluru R
    Int J Adolesc Med Health; 2011; 23(3):167-73. PubMed ID: 22191179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs for treatment of ADHD.
    Treat Guidel Med Lett; 2011 May; 9(105):23-8; quiz 2 p following 28. PubMed ID: 21519317
    [No Abstract]   [Full Text] [Related]  

  • 31. New treatments and approaches for attention deficit hyperactivity disorder.
    Newcorn JH
    Curr Psychiatry Rep; 2001 Apr; 3(2):87-91. PubMed ID: 11276402
    [No Abstract]   [Full Text] [Related]  

  • 32. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV; Wigal SB; Hodgkins P
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MTA at 8.
    Pliszka SR
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1122. PubMed ID: 19855222
    [No Abstract]   [Full Text] [Related]  

  • 35. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
    Bushe CJ; Savill NC
    J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 38. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
    Prasad S; Steer C
    Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.
    Brown TE
    J Child Adolesc Psychopharmacol; 2004; 14(1):129-36. PubMed ID: 15142400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.